Ajanta Pharma Q1 FY27 Results Analysis: US Generics Surge 57%, Asia Generics Decline 16% (AJANTPHARM)
Ajanta Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,625.96 Cr (+24.82% YoY) and PAT growth of +30.89% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 30, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 1,625.96 Cr (+24.82% YoY) |
| PAT (Q1) | Rs. 334.22 Cr (+30.89% YoY) |
| EBITDA margin | 26.05% (-92 bps YoY) |
| EPS (Q1) | Rs. 26.75 (+30.87% YoY) |
| Market cap | Rs. 42,932.88 Cr |
| CMP | Rs. 3,436.40 |
Quarter Snapshot
Ajanta Pharma delivered a strong Q1 with 24.8% revenue growth and 30.9% PAT growth, driven by a massive 57% surge in US generics (far above guidance) and India branded generics outperforming the market. However, Asia branded generics declined 16% (missed guidance) and the effective tax rate rose. The company's adjusted EBITDA margin of 28.0% was within guidance, and the dividend was raised. Overall, a solid quarter with a key growth surprise in US, but Asia remains a concern.
Key Investment Insights
Key Positives
- Revenue grew 24.8% YoY to Rs.1,625.96 Cr, highest quarterly growth in at least five quarters.
- PAT grew 30.89% YoY to Rs.334.22 Cr, EPS at Rs.26.75.
- US Generics revenue grew 57% YoY, far exceeding management's mid-single-digit guidance.
- India branded generics grew 24% YoY, outperforming IPM growth of 11%.
- Adjusted EBITDA margin of 28.0% was within the guided band of 27%±1%.
- Interim dividend raised to Rs.32 per share from Rs.28 per share.
- 3 ANDA approvals received in Q1, with 2 launched.
Risk Factors
- Asia branded generics declined 16% YoY, missing management's low double-digit growth guidance.
- Effective tax rate rose to 25.20% from 22.89% in Q1 FY26 due to one manufacturing facility transitioning out of tax exemption.
- Forex volatility remains lumpy; net gain this quarter but reported EBITDA margin compressed 92 bps YoY to 26.05% due to forex losses.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.